Home > Insider Trading > Filing (0000899243-17-006500)

Filing Details

Accession Number:: 0000899243-17-006500
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-03-03 19:19:22
Reporting Period:: 2017-02-22

Filing Date:: 2017-03-03
Accepted Time:: 2017-03-03 19:19:22
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1103021	Biodelivery Sciences International Inc	BDSI	Pharmaceutical Preparations (2834)	352089858

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1662930	Niraj Vasisht	C/O Biodelivery Sciences Intl, Inc., 4131 Parklake Ave., Suite 225 Raleigh NC 27612	Svp & Chief Technology Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-02-22	24,980	$0.00	196,802	No	4	M	Direct
Common Stock	Disposition	2017-02-22	9,500	$2.01	187,302	No	4	S	Direct
Common Stock	Acquisiton	2017-02-23	66,667	$0.00	253,969	No	4	M	Direct
Common Stock	Disposition	2017-02-23	23,500	$1.95	230,469	No	4	S	Direct
Common Stock	Acquisiton	2017-03-01	50,000	$0.00	280,469	No	4	M	Direct
Common Stock	Disposition	2017-03-01	9,000	$2.03	271,469	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Acquisiton	2017-02-22	24,980	$0.00	24,980	$0.00
Common Stock	Restricted Stock Units	Acquisiton	2017-02-23	66,667	$0.00	66,667	$0.00
Common Stock	Restricted Stock Units	Acquisiton	2017-03-01	50,000	$0.00	50,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2017-02-22	2017-02-22	No	4	M	Direct
66,666	2017-02-23	2018-02-23	No	4	M	Direct
100,000	2017-03-01	2019-03-01	No	4	M	Direct

Footnotes

The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan").
The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs.
On February 22, 2017, the Reporting Person sold an aggregate of 9,500 shares of the Issuer's Common Stock at a weighted average price of $2.01 per share. The highest sale price for the Common Stock was $2.06 per share and the lowest sale price was $1.96 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018.
On February 23, 2017, the Reporting Person sold an aggregate of 23,500 shares of the Issuer's Common Stock at a weighted average price of $1.95 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019.
On March 1, 2017, the Reporting Person sold an aggregate of 9,000 shares of the Issuer's Common Stock at a weighted average price of $2.03 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.